About Cerebricon
Cerebricon is a Healthcare company based in Kuopio (Finland) founded in 2000, and was acquired by Charles River Laboratories in August 2009. Preclinical research services for CNS and PNS diseases are provided. The company has 52 employees. Its Indian entity Charles River Laboratories India Private Limited reported revenue of ₹99.82 Cr. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Neurology.
Company details
Cerebricon was established in 2000 in Kuopio, Finland, as a provider of preclinical research services targeting central nervous system (CNS) and peripheral nervous system (PNS) diseases. Operations focus on the biotechnology sector, where support is given for early-stage drug development and testing in neurological disorders. Services encompass in vivo and in vitro models, efficacy assessments, and safety evaluations, conducted primarily from the companys base in northern Europe.
- Headquarters Kuopio, Finland
- Employees 52
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cerebricon.com
- Acquired by Charles River Laboratories (Aug 2009)
- Legal Name Charles River Laboratories India Private Limited
- Date of Incorporation 08 Oct, 2008
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹99.82 Cr
FY 2025 · +15% YoY
- Indian entity net profit₹5.35 Cr
FY 2025 · 5% margin
- Indian entity EBITDA₹7.95 Cr
FY 2025 · 8% margin
- Investors
- Employee Count52
- Acquired byCharles River Laboratories
(Aug 2009)
Associated legal entities of Cerebricon
Cerebricon operates through Charles River Laboratories India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories India Private Limited CIN U24119KA2008PTC047975 | Active | 08 Oct 2008 | Bangalore, Karnataka | ₹99.8 Cr | 52 | 6 | View details |
Investors in Cerebricon
Cerebricon has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Charles River Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States |
Investor details for Cerebricon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Charles River Laboratories India Private Limited (Cerebricon)
Charles River Laboratories India Private Limited is the primary company behind Cerebricon. The board of Charles River Laboratories India Private Limited currently have 5 directors; the longest-serving is Prafulla Krishnaji Chitnis, appointed in 2009. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Prafulla Krishnaji Chitnis DIN 02476050 | Managing Director | 02 Jan 2009 | 17 yrs 9 mo | Charles River Laboratories India Private Limited |
| Kevin John Finn DIN 09706567 | Director | 25 Aug 2022 | 4 yrs 1 mo | Charles River Laboratories India Private Limited |
| Jon Galli DIN 09799394 | Director | 13 Dec 2022 | 3 yrs 10 mo | Charles River Laboratories India Private Limited |
| Amro Elabbas DIN 11149457 | Additional Director | 11 Jun 2025 | 1 yr 4 mo | Charles River Laboratories India Private Limited |
| Rajesh Puthiya Sudhakaran DIN 11463270 | Managing Director | 12 Jan 2026 | 9 mo | Charles River Laboratories India Private Limited |
Financials of Cerebricon
Figures of Charles River Laboratories India Private Limited, the primary company behind Cerebricon, for FY 2025. Revenue was ₹99.82 Cr (+15% year on year). Net profit was ₹5.35 Cr (5% margin). EBITDA was ₹7.95 Cr (8% margin). Revenue has grown at a compounded annual rate of +12% over three years and +10% over five years.
- ₹99.82 CrRevenue · FY 2025 · +15% YoY
- ₹5.35 CrNet profit · 5% margin
- ₹7.95 CrEBITDA · 8% margin
- ₹28.79 CrPaid-up capital
- 52Employees (provident fund records)
- +12%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Charles River Laboratories India Private Limited are on its company page.
Detailed financial statements for Cerebricon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cerebricon
2 dated milestones of Cerebricon across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Cerebricon is founded.
- Exit Acquired by Charles River Laboratories.
Web traffic of Cerebricon
Websites that share an audience with Cerebricon (cerebricon.com).
Websites whose visitors overlap most with Cerebricon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| marinbio.com | 100% | 4.9K | #4,360,368 | View details | |
| biomodels.com | 100% | 2.5K | #9,156,523 | View details | |
| molprofiles.co.uk | 100% | View details | |||
molecularimaging.com | molecularimaging.com | 100% | – | ||
biodevelopment.com | biodevelopment.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Cerebricon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cerebricon
Complete news archive for Cerebricon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerebricon
Cerebricon was founded in 2000.
Cerebricon is headquartered in Kuopio, Finland.
Cerebricon has 52 employees.
The primary company behind Cerebricon, Charles River Laboratories India Private Limited, reported revenue of ₹99.82 Cr for FY 2025, up 15% year on year.
Cerebricon was established in 2000 in Kuopio, Finland, as a provider of preclinical research services targeting central nervous system (CNS) and peripheral nervous system (PNS) diseases. Operations focus on the biotechnology sector, where support is given for early-stage drug development and testing in neurological disorders. Services encompass in vivo and in vitro models, efficacy assessments, and safety evaluations, conducted primarily from the companys base in northern Europe.
Cerebricon has 1 investor. Key investors include Charles River Laboratories.
Cerebricon operates through Charles River Laboratories India Private Limited.
Yes. Cerebricon was acquired by Charles River Laboratories in August 2009.
The legal entities of Cerebricon currently have 6 directors, including Prafulla Krishnaji Chitnis, Kevin John Finn, Jon Galli and others.